Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Fate Therapeutics, Inc.”

40 pharma patents match "Fate Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 40
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 40 pharmaceutical patents matching "Fate Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

40 results for “Fate Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  2. US 12410403

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  3. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  4. US 12385012

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  5. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  6. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  7. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  8. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  9. US 12203098

    Cells having solid tumor targeting backbone and use thereof

    Fate Therapeutics, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  10. US 12173274

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  11. US 12122846

    Chimeric antigen receptor for tumor targeting

    Fate Therapeutics, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  12. US 12036241

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Granted Jul 16, 2024 · Expires Jul 11, 2044

    granted
  13. US 11932870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  14. US 11851677

    Composition and methods for inducing myeloid suppressive cells and use thereof

    Fate Therapeutics, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  15. US 11634688

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  16. US 11413309

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted
  17. US 11365394

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  18. US 11352607

    Genomic engineering of pluripotent cells

    Fate Therapeutics, Inc. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  19. US 11162075

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted
  20. US 11162076

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted
  21. US 11135244

    Stem cell culture media and methods of enhancing cell survival

    Fate Therapeutics, Inc. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted
  22. US 11096964

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Granted Aug 24, 2021 · Expires Aug 19, 2041

    granted
  23. US 11072781

    Genomic engineering of pluripotent cells

    Fate Therapeutics, Inc. · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted
  24. US 11052118

    Enhanced stem cell composition

    Fate Therapeutics, Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted